Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Article Details
- CitationCopy to clipboard
Narayanan S, Kunz PL
Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Hematol Oncol Clin North Am. 2016 Feb;30(1):163-77. doi: 10.1016/j.hoc.2015.09.008.
- PubMed ID
- 26614375 [ View in PubMed]
- Abstract
Neuroendocrine tumors (NETs) are rare epithelial neoplasms with neuroendocrine differentiation originating most commonly in the lungs and gastroenteropancreatic. Treatment includes surgery and other local therapies; treatment of inoperable disease centers around symptom management and control of tumor growth. Somatostatin analogues (SSAs) have been a mainstay of managing hormone-related symptoms. Emerging evidence suggests that they are effective therapies for tumor control also. Peptide receptor radionuclide therapy with radiolabeled SSAs is a new, promising treatment for inoperable or metastatic NETs. This article reviews the role of SSAs in the treatment of NETs.
DrugBank Data that Cites this Article
- Drugs